NeoGenomics (NASDAQ:NEO - Get Free Report) released its quarterly earnings data on Tuesday. The medical research company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.05), Zacks reports. The business had revenue of $172.00 million during the quarter, compared to analyst estimates of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%.
NeoGenomics Stock Performance
Shares of NEO traded down $0.76 during midday trading on Friday, hitting $11.10. 1,877,797 shares of the stock traded hands, compared to its average volume of 1,178,573. NeoGenomics has a 1-year low of $10.69 and a 1-year high of $19.11. The firm has a market capitalization of $1.43 billion, a PE ratio of -17.90 and a beta of 1.23. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. The business's 50 day moving average price is $15.28 and its two-hundred day moving average price is $15.49.
Wall Street Analyst Weigh In
A number of equities analysts have commented on NEO shares. The Goldman Sachs Group decreased their price objective on shares of NeoGenomics from $20.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Benchmark downgraded shares of NeoGenomics from a "buy" rating to a "hold" rating in a report on Monday, January 13th. Jefferies Financial Group started coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They issued a "buy" rating and a $22.00 price objective for the company. Needham & Company LLC decreased their price objective on shares of NeoGenomics from $19.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday. Finally, Bank of America decreased their price objective on shares of NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a report on Wednesday. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, NeoGenomics presently has an average rating of "Moderate Buy" and an average price target of $19.80.
Check Out Our Latest Research Report on NEO
About NeoGenomics
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Featured Stories
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
